知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

310 条记录 (耗时 0.026 秒)

    RNA for treatment or prophylaxis of a liver disease
    3.
    发明授权
    RNA for treatment or prophylaxis of a liver disease 有权

    公开(公告)号：US11464836B2

    公开(公告)日：2022-10-11

    申请号：US16466630

    申请日：2017-12-08

    申请人： CureVac AG

    发明人： Nigel Horscroft ,  Marion Pönisch ,  Christine Weinl-Tenbruck ,  Frédéric Chevessier-Tünnesen

    IPC分类号： C07H21/02 ,  C07H21/04 ,  A61K38/48 ,  A61P1/16 ,  A61K38/17 ,  A61K38/18 ,  A61K38/19 ,  C12N15/11

    摘要： The present invention relates to an RNA suitable for treatment or prophylaxis of liver diseases. In particular, the present invention provides an RNA encoding at least one peptide or protein selected from the group consisting of an extracellular matrix protease, CCAAT/enhancer-binding protein alpha (CEBPA), TNF-related apoptosis-inducing ligand (TRAIL), Hepatocyte Growth Factor (HGF), hepatocyte nuclear factor 4 alpha (HNF4A), fibroblast growth factor 21 (FGF21), opioid growth factor receptor-like 1 (OGFRL1), Relaxin 1 (RLN1), Relaxin 2 (RLN2) and Relaxin 3 (RLN3), or a fragment or a variant of any of these peptides or proteins. The present invention concerns said RNA as well as compositions and kits comprising the RNA. Furthermore, the present invention relates to the RNA, compositions or kits as disclosed herein for use as a medicament, in particular for treatment or prophylaxis of a liver disease. The present invention also provides the use of the RNA, compositions or kits as disclosed herein for increasing the expression of said encoded protein, in particular in gene therapy.

    ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION
    4.
    发明申请
    ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION 有权

    公开(公告)号：US20220307040A1

    公开(公告)日：2022-09-29

    申请号：US17713533

    申请日：2022-04-05

    申请人： CureVac AG

    发明人： Andreas THESS ,  Thomas SCHLAKE ,  Stefanie GRUND

    IPC分类号： C12N15/67 ,  A61K39/12 ,  C12N15/85 ,  A61K39/145 ,  A61K39/205 ,  C12N15/68

    摘要： The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3′-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.

    NUCLEIC ACID BASED COMBINATION VACCINES
    7.
    发明申请
    NUCLEIC ACID BASED COMBINATION VACCINES 有权

    公开(公告)号：US20220211838A1

    公开(公告)日：2022-07-07

    申请号：US17665704

    申请日：2022-02-07

    申请人： CureVac AG

    发明人： Cornelia OOSTVOGELS ,  Benjamin PETSCH ,  Susanne RAUCH ,  Kim Ellen SCHWENDT

    IPC分类号： A61K39/145 ,  A61K39/155 ,  C07K14/005 ,  C12N7/00

    摘要： The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The invention is also directed to first and second and further medical uses of the pharmaceutical compositions and combination vaccines, and to methods of treating or preventing a Coronavirus infection and a further virus infection.

    ARTIFICIAL NUCLEIC ACID MOLECULES
    9.
    发明申请
    ARTIFICIAL NUCLEIC ACID MOLECULES 有权

    公开(公告)号：US20220136001A1

    公开(公告)日：2022-05-05

    申请号：US17576583

    申请日：2022-01-14

    申请人： CureVac AG

    发明人： Andreas THESS

    IPC分类号： C12N15/85 ,  C12N15/67

    摘要： The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-UTR) element comprising a nucleic acid sequence which is derived from the 3′-UTR of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3′-UTR element comprising a nucleic acid sequence which is derived from the 3′-UTR of a ribosomal protein gene for enhancing, stabilizing and/or prolonging protein expression from a nucleic acid sequence comprising such 3′-UTR element.

    COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC)
    10.
    发明申请
    COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) 有权

    公开(公告)号：US20220096616A1

    公开(公告)日：2022-03-31

    申请号：US17378954

    申请日：2021-07-19

    申请人： CureVac AG

    发明人： Marijke BARNER ,  Jochen PROBST ,  Thomas LANDER ,  Ingmar HOERR

    IPC分类号： A61K39/00

    摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.